Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Journal
Translational Cancer Research
Journal Volume
5
Pages
S907-S912
Date Issued
2016
Author(s)
SDGs
Other Subjects
epidermal growth factor receptor 2; pertuzumab; trastuzumab; adjuvant therapy; breast cancer; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; cancer survival; drug use; human; long term survival; neoadjuvant therapy; Note; treatment response
Publisher
AME Publishing Company
Type
note